http://www.proseedcapital.com/en Thu, 31 Dec 2009 01:52:28 +0000 http://backend.userland.com/rss092 en http://www.proseedcapital.com/en/2009/12/egalet-and-redhill-biopharma-enter-into-an-exclusive-license-agreement/ http://www.proseedcapital.com/en/2009/06/lifeline-scientific-inc-trial-results-published-at-american-transplant-congress/ http://www.proseedcapital.com/en/2009/04/amarins-amr101-for-huntingtons-disease-marketing-authorization-application-accepted-for-review-by-emea/ http://www.proseedcapital.com/en/2008/07/amarin-proceeding-to-phase-3-with-amr101-for-hypertriglyceridemia/ http://www.proseedcapital.com/en/2008/06/lifeline-wins-contracts-to-supply-largest-canadian-transplant-programmes/ http://www.proseedcapital.com/en/2008/04/kamada-announces-that-it-had-succesfully-met-the-primary-endpoint-in-its-us-phase-iii-clinical-trial-with-intravenous-aat/ http://www.proseedcapital.com/en/2008/03/lifeline-division-wins-contracts-to-supply-two-leading-transplant-centres/ http://www.proseedcapital.com/en/2008/01/amarin-to-commence-phase-ii-trial-with-amr101-in-age-associated-memory-impairment/ http://www.proseedcapital.com/en/2008/01/lifeline-scientific-announces-successful-completion-of-ipo/ http://www.proseedcapital.com/en/2007/12/amarin-acquires-ester-neurosciences/